Year-end Report
May-April 2024/2025

Positive development in the USA continues

SEK t	Q4 24/25	Q4 23/24	May-April 24/25	May-April 23/24
Net sales	2,332	1,899	8,619	7,290
Operating profit (loss)	-20,341	-41,490	-85,839	-126,845
Profit (loss) for the period	-20,766	-39,532	-87,624	-124,823
Earnings per share after dilution	-0.21	-0.47	-0.95	-2.14
Number of shares at the end of the period	97,786,384	84,055,560	92,569,248	84,055,560
Cash and cash equivalents at the end of the period	24,415	79,407	24,415	79,407
Cash flow from operating activities	-17,826	-25,251	-85,367	-114,575
Average number of employees	26	35	27	37

Biovica in brief – Treatment decisions with greater certainty

- Biovica's vision is: "Improved care for cancer patients."
- Biovica develops and commercializes the blood-based biomarker assay, DiviTum TKa, which enables early-stage evaluation of treatment effectiveness. The initial focus is on breast cancer.
- The initial focus area is metastatic breast cancer, however study results since 2024 show that DiviTum TKa can also serve as both a predictive and prognostic tool in the adjuvant treatment of early-stage breast cancer.
- DiviTum TKa has obtained FDA 510(k) clearance in the USA and has CE marking in the EU.
- Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B).
- FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com

Webcast:
When: 18 June 2025, 3 PM to 4 PM CET
Where: register via: https://www.eventbrite.com/e/biovica-q4-earnings-call-2024-25-tickets-1392516366939
Broadcast language: in English

Significant events during the fourth quarter

- *Biovica signed an agreement with Eurobio Scientific covering 60% of the European market*
- Biovica has secured a new work order worth SEK 2.5 million for TKa testing services in the Pharma Services part of the business
- *Biovica and Outcomes4Me have embarked on a new collaboration to empower patients with metastatic breast cancer to better understand how well their treatment is working*
- *DiviTum TKa data in combination with inflammation proteins presented at the AACR meeting enhance precision to predict efficacy of immunotherapy*

Significant events during the third quarter

- *DiviTum TKa results presented at ASCO, the world's largest cancer conference*
- *Biovica signed new drug development agreement*
- *Extraordinary general meeting of Biovica International AB*
- *Biovica carried out a directed new issue of units for approximately SEK 16.4 million*
- *Biovica signed an agreement with US Biotech company in clinical phase*
- *Biovica secured a significant order for TKa testing services*
- *Biovica published the outcome of exercise of warrants from series TO3B.*
- *Biovica signed a master service agreement (MSA) with UK biotech company*
- *NewDivitum TKa data that significantly increases the market potential presented at SABCS*
- *Biovica signed an agreement with US healthcare and insurance giant*
- *Biovica's CLIA lab obtained a permit from the state of New York, which opens up the entire US market*
- *Biovica secured yet another significant order for TKa testing services*

Significant events after the end of the period

- *Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa*
- *Biovica signed a significant Master Service Agreement (MSA) and first work under that agreement for SEK 4 million*
- *New data on DiviTum TKa use in three areas of cancer presented at ASCO*
- *Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business*
- *Biovica announced financial targets subsequent to important partnership and commercial success*
- *Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share*
- *Notice issued of extraordinary general meeting of Biovica International AB*
- *Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA*

CEO's comments

Important steps were made during the 2024/2025 financial year to establish DiviTum TKa as a standard approach to treatment monitoring in breast cancer. Strong clinical evidence, commercial success and new strategic partnerships have played a key role in solidifying our position in the US and European markets.
Compared to the previous quarter, our sales in the USA increased by more than 25% in the fourth quarter and the positive trend has extended into the new fiscal year, following the recent close of our books.

We have continued generating new clinical evidence for DiviTum TKa. The results from three cancer studies were presented at the 2025 ASCO Annual Meeting, which is the largest oncology conference in the world. The most impactful results, however, were those presented at the San Antonio Breast Cancer Symposium (SABCS) in December, where seven breast cancer studies – including two focused on early-stage disease – were shared. It opens up a new, very large market for us, with estimated market potential of up to USD 3 billion. There is a significant need within the healthcare industry to optimize and streamline the use of costly treatments – such as CDK4/6 inhibitors. This is where DiviTum TKa makes a real difference – providing evidence-based, cost-effective decision support.

Further confirmation came in the form of a new agreement with a leading US healthcare and insurance giant with more than 10 million policyholders and annual revenue in excess of USD 100 billion. This organization – which serves as both a healthcare provider and health insurer – has observed that policyholders are at times prescribed costly treatments that are not always effective. The use of DiviTum TKa can enhance patient outcomes – while dramatically lowering costs for the organization. The agreement makes it possible to establish DiviTum TKa as one of their standard routines for breast cancer treatment.

In May 2025, we also began a collaboration with the US-based diagnostics company Tempus AI, which will offer DiviTum TKa nationwide through its network of hundreds of sales representatives in the oncology field. Tempus AI has an impressive track record, with annual revenue growth exceeding 30%. Biovica's CLIA-certified laboratory will serve as a reference lab to Tempus AI, which will enable them to include DiviTum TKa in their collection of precision medicine solutions currently offered to more than 6,500 oncologists.

Within our Pharma Services business, we continued to strengthen our relationships with the pharmaceutical industry throughout the year. Subsequent to the end of the period, we signed two new MSAs with Tier 1 (annual revenue exceeding USD 10 billion) pharmaceutical companies. An initial order of approximately SEK 5 million has already been received, with call-offs expected to take place over the next 2 to 3 years. This means that we now have 18 MSAs in place, including 5 with Tier 1 companies, representing a contract volume of approximately SEK 25 million in revenue to be recognized over the next 2 to 3 years as the services are delivered. This will be a key factor in achieving the financial targets that we have announced and an important step towards more comprehensive collaborations that could lead to new, customer-financed Companion Diagnostic (CDx) products.

An additional key milestone this year was our new collaboration with Eurobio Scientific – a leading in vitro diagnostics company – which expands our commercial reach across Europe. It opens the door to eight key European markets, which together account for 60% of our priority EU markets. The combination of Eurobio's extensive hospital and laboratory network with our technology lays a strong foundation for increased test adoption across Europe.

We are entering the new fiscal year with renewed confidence and increased market penetration – driven in part by the recent approval for our CLIA laboratory to offer DiviTum TKa to residents of New York State, as well as the growing interest we are seeing from both commercial partners and the clinical community. Our robust network of partners and growing presence in the clinical space position us well for continued growth, which is also reflected in the financial targets that we recently announced. The goal is to increase sales to SEK 50 million during the 2025/2026 fiscal year, derived primarily from the USA and Pharma Services.

At the beginning of the financial year, we completed a targeted new share issue of SEK 16.4 million to support the continued commercialization and development of our operations. Participation came from both existing shareholders and new institutional investors. Subsequent to the end of the period there is also a rights issue underway and we are hoping for a high level of participation. Our assessment is that the guaranteed amount of SEK 80 million, based on the current business plan and in line with our previously communicated financial target, will sufficiently cover our needs until the point when the company is cash flow positive around the turn of the year 2026/2027.

I would like to sincerely thank our employees, investors, clinical partners and everyone else who has contributed to our success during the year. Together, we will take the next steps toward improving treatment outcomes and quality of life for cancer patients throughout the world.

Anders Rylander, CEO

Anders Rylander, CEO

Significant events during the fourth quarter

Biovica signed an agreement with Eurobio Scientific covering 60% of the European market
Biovica has entered into a collaboration agreement with Eurobio Scientific, a leading French group specializing in in vitro specialty medical diagnostics and life sciences, to introduce DiviTum TKa in Austria, Benelux, France, Germany, Switzerland, and the UK. The scope of the agreement covers 60 percent of the total market potential identified as key European markets for Biovica.

Biovica has secured a new work order worth SEK 2.5 million for TKa testing services in the Pharma Services part of the business.
It is the third work order submitted by this customer, bringing the combined total for all three to SEK 7 million. They are a U.S. East Coast clinical-stage biotech specializing in small molecule oncology drugs. Biovica has a Master Service Agreement (MSA) with them and DiviTum TKa is currently being used in two ongoing Phase I trials, both evaluating various CDK inhibitor candidates. This latest work order, set to run for 1.5 years from Q3 2025, adds a third drug candidate and clinical study, further strengthening the long-term partnership.

Biovica and Outcomes4Me have embarked on a new collaboration to empower patients with metastatic breast cancer to better understand how well their treatment is working
Biovica has entered into a collaboration with Outcomes4Me, the developer of a leading direct-to-patient empowerment platform that provides personalized, evidence-based guidance to individuals diagnosed with cancer. The platform currently serves a community of approximately 250,000 members.

DiviTum TKa data in combination with inflammation proteins presented at the AACR meeting enhance precision to predict efficacy of immunotherapy
An abstract featuring DiviTum TKa as part of a biomarker algorithm was presented by Karolinska Institutet (KI) at the AACR Annual Meeting 2025, held in Chicago from April 25 through 30. This provides the first evidence that DiviTum TKa, when combined with inflammatory proteins, significantly improves the ability to stratify patients who are likely to benefit from immunotherapy.
A translational study in malignant melanoma, conducted by Karolinska Institutet (KI) and Karolinska University Hospital, demonstrated a five-year survival rate of 83 percent among patients with the most favorable biomarker profile – compared to 11 percent in a high-risk cohort. The full study results were presented on Sunday, 27 April at 2:00 PM.

Summary of significant events during the third quarter

DiviTum TKa results presented at ASCO, the world's largest cancer conference.
Results with DiviTum TKa from the GEICAM/2014-12 FLIPPER trial in Spain were presented at the world's largest cancer conference, ASCO. The data supports the use of DiviTum TKa to predict outcome and progression on first line treatment of HR+ metastatic breast cancer (MBC) patients, thus providing important clinical information on treatment benefits.

Biovica signed new drug development agreement
Biovica signed a master service agreement with a US-based biopharma company specializing in breast cancer. The first work order was also received. The agreement enables Biovica to provide TKa testing services in conjunction with pre-clinical and clinical trials aimed at developing new treatments. The initial work order is valued at SEK 0.75 million.

Extraordinary general meeting of Biovica International AB
In accordance with the proposal by the Board of Directors, the EGM resolved to implement the following long-term incentive program:
Share savings program 2024/2027:1 for all of Biovica's employees in Sweden and Denmark.
Share savings program 2024/2027:2 for the company's Board of Directors, in accordance with shareholder Mats Danielsson's proposal.
Stock option program 2024/2027:1 for senior executives and employees of the company's US subsidiary.
Performance share program 2024/2027:1 for senior executives and employees of the company's US subsidiary.

Biovica carried out a directed new issue of units for approximately SEK 16.4 million
Based on the authorization from the Annual General Meeting on September 5, 2023, the Board of Directors of Biovica International AB (publ) has carried out a directed issue of units. The proceeds,

prior to issue costs, amount to approximately SEK 16.4 million.

Biovica signed an agreement with US Biotech company in clinical phase
In accordance with this Master Service Agreement (MSA), Biovica will be providing TKa analyses and expertise in interpreting the results to support both drug development and for dose optimization.

Biovica secured a significant order for TKa testing services
Biovica has received an order worth SEK 2.2 million for TKa testing services in the Pharma Services part of the business. It is Biovica's largest single work order to date. The client is a US-based biotech company focused on next-generation CDK inhibitors.

Biovica published the outcome of exercise of warrants from series TO3B.
Biovica has published the outcome of exercise of warrants from series TO3B that were issued in October 2024 as part of the Company's rights issue of units. A total of 7,441,387 warrants were exercised for subscription of the equivalent amount of class B shares in the Company, which corresponds to a subscription rate of 42.73 percent. Biovica will thus receive approximately SEK 19.4 million prior to issue costs, which are estimated at approximately SEK 1.5 million.

Biovica signed a master service agreement (MSA) with UK biotech company
Biovica has signed an MSA for TKa testing services with a biotech company based in the UK. Including this agreement, Biovica has now signed 5 MSA's thus far in 2024.

NewDivitum TKa data that significantly increases the market potential presented at SABCS
A total of 7 abstracts of studies where DiviTum TKa has been used was presented at the world's largest breast cancer conference, the San Antonio Breast Cancer Symposium (SABCS), during 10-13 December 2024. Two of the abstracts validated DiviTum TKa for adjuvant (early breast cancer) therapy, which opens up a new market opportunity for Biovica that increases the addressable market in the area of breast cancer by USD 3 billion per year in the company's key markets (USA, Europe and Japan).

Biovica signed an agreement with US healthcare and insurance giant
Biovica has signed a Client Billing agreement with one of the largest US healthcare and insurance providers. The company's annual revenue exceeds USD 100 billion. There are more than 10 million policyholders insured by this company in the USA as their healthcare and health insurance provider. The company has already started using DiviTum TKa and it recognizes the benefits that it offers to patients, along with the social benefits via its budget impact.

Biovica's CLIA lab obtained a permit from the state of New York, which opens up the entire US market
Biovica has obtained a permit for offering the assay to patients residing in the state of New York. Together with the prior permits, it makes DiviTum TKa available in all 50 states, as well as Puerto Rico.

Biovica secured yet another significant order for TKa testing services
Biovica secured an order for SEK 2.3 million for TKa testing services in the Pharma Services part of the business. It is with a UK-based pharma/biotech company to be used in a phase I/II clinical study in patients with advanced solid tumors being treated with a next generation CDK inhibitor.

Significant events after the end of the period

Biovica is collaborating with Tempus to expand the commercial reach of DiviTum TKa
Biovica has embarked on a collaboration with Tempus, a leader in AI and data-driven precision medicine. Tempus will offer DiviTum TKa, as part of its comprehensive portfolio of diagnostics for oncologists. Tempus currently collaborates with more than 6,500 oncologists in the United States, providing precision medicine solutions aimed at helping physicians deliver individualized care to their patients. The collaboration significantly expands Biovica's market reach by leveraging Tempus' established sales network.

Biovica announced that it has signed a Master Service Agreement (MSA) with a US-based pharma/biotech company.
The company is widely recognized as a Tier 1 player in oncology. An initial work order valued at SEK 4 million has also been signed.
As part of the agreement, Biovica will provide TKa testing for multiple projects using its DiviTum TKa

assay, along with its expertise in interpreting TKa dynamics to support drug development. The first work order relates to a large-scale clinical trial in breast cancer. The total expected revenue from the first work order amounts to approximately SEK 4 million.

New data on DiviTum TKa use in three areas of cancer presented at ASCO

New data on the use of DiviTum TKa in three cancer indications was presented at the 2025 ASCO Annual Meeting, held in Chicago from May 30 through June 3. ASCO – the American Society of Clinical Oncology – is the world's largest cancer congress with a focus on clinical research and care. The new data further reinforces DiviTum TKa's role as a predictive biomarker across three different cancer indications:

- Hormone receptor–positive (HR+) metastatic breast cancer (MBC) in patients treated with CDK4/6 inhibitors, as studied in the high-profile PEARL trial
- BRAF V600–mutated metastatic melanoma treated with immune checkpoint inhibitors (ICIs)
- Ovarian cancer treated with platinum-based chemotherapy

While the PEARL study is a large-scale trial addressing a key clinical decision point in metastatic breast cancer – the choice between newer and established treatment combinations – the studies in melanoma and ovarian cancer are more exploratory in nature.

Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business

Biovica announced that it has signed three new work orders in the Pharma Services part of the business with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers. Two of the three work orders were placed by the Us-based Tier 1 pharmaceutical company (with revenues exceeding USD 10 billion) that recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million order. These latest orders will support development of next generation CDK4/6 inhibitors. The assignments include a combination of retrospective analyses, to be conducted over the coming months, and prospective analyses, scheduled to take place over an estimated two-year period.

Biovica announced financial targets reflecting its important partnerships and commercial success

Biovica announced financial targets for the next two fiscal years. The targets reflect the company's recent commercial success and its long-term commitment to transparency and value creation for patients, healthcare providers and shareholders. The recently announced collaboration with the US-based diagnostics company Tempus AI along with Biovica's agreement with a leading healthcare provider (announced in December 2024) are expected to generate significant revenue for the company. With more than 15 active collaborations with pharmaceutical companies totaling approximately SEK 25 million in project value, and 18 partnership agreements covering key European markets, Biovica has thus established a strong platform for growth. This now puts Biovica in a position to communicate a clear financial direction.

Biovica's financial targets are:
• Fiscal year 2024/25 (ending 30 April 2025): Net sales of SEK 8.5 million
• Fiscal year 2025/26: Net sales of SEK 50 million
• Fiscal year 2026/27: Net sales of SEK 150 million

With expected operating expenses at the current level of approximately SEK 90 million per year, Biovica anticipates that it will become cash flow positive during the third quarter of the 2026/27 financial year.

Anticipated revenue distribution for FY25/26 and FY26/27:
• 65% from the US market driven by compensation and volume growth via strategic partnerships
• 30% from the Pharma Services part of the business based on current and future biomarker collaborations
• 5% from European partners via distributor and laboratory agreements in 18 countries

Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share

The Board of Directors of Biovica International AB (publ) ("Biovica" or the "Company") has today, subject to subsequent approval by an extraordinary general meeting, resolved to carry out a new issue of A-shares and B-shares of approximately SEK 80.1 million with preferential rights for the Company's shareholders (the "Rights Issue") and a directed issue of warrants of series TO4B to investors who have entered into guarantee undertakings as top-down guarantors (the "Anchor Investors") (the

"Directed Issue of Warrants") In addition, the Board of Directors has proposed that an extraordinary general meeting resolves to authorize the Board of Directors to resolve on a directed issue of up to 83,291780 B-shares to the Anchor Investors, provided that the Anchor Investors have not received full allotment in the Rights Issue (the "Oversubscription Option"). The Rights Issue is covered to approximately SEK 80.1 million, corresponding to 100 percent through a combination of subscription and top-down and bottom-up guarantee undertakings. As compensation for the top-down guarantee undertakings in the Rights Issue, free warrants will be issued and allotted in the Directed Issue of Warrants. As compensation for the bottom-up guarantee undertakings, the guarantors will receive a cash compensation of eight percent of the respective guarantors' guaranteed amount.

The rationale of the Rights Issue is to (i) continue the Company's focused launch in the US, (ii) conduct service development within pharma, (iii) conduct commercialization in Europe through partnerships where agreements are already signed, and (iv) develop product and production capacity to meet expected volumes, customer needs, and regulatory requirements. The net proceeds from the Rights Issue are expected to cover the Company's working capital needs through Q3 of fiscal year 2026/27, by which time Biovica expects to become cash-flow positive.

Notice of Extraordinary General Meeting of Biovica International AB
The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm. For details and agenda, please see the press release published on the company's website www.biovica.com

Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA
Biovica has signed a new MSA with a US-based Tier 1 pharmaceutical company. The company has also placed an initial work order of approximately SEK 800 thousand. This new customer, a global leader in oncology drug development, is the fifth Tier 1 biopharma company to join Biovica's Pharma Services customer base.
The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum TKa.

Other

2025 AGM
Biovica's Annual General Meeting will be held on 16 September 2025 in Uppsala. Notice of the AGM will be published on Biovica's website, in Post- och Inrikes Tidningar (gazette) and in SvD (newspaper). The Board of Directors proposes that no dividends should be distributed to shareholders.

Comments on the financial performance of the Group

Q4 - Sales and earnings

Net sales for the period amounted to SEK 2,332 (1,899) thousand. It corresponds to an increase of 21%, primarily driven by a more twofold increase in sales in the USA compared to the same period last year. Fourth quarter sales are attributable to three different product groups. These are: Tests (IVD) for the US market, Tests (RUO) and DiviTum Kits (RUO) which are primarily sold to the pharmaceutical industry and used for research purposes. More information is provided in Note 1

The operating loss for the period was SEK -20,341 (-41,490) thousand.

Net financial items amounted to SEK 100 (656) thousand. Loss after financial items was SEK -20,240 (-40,834) thousand. Loss for the period was SEK -20,766 (- 39,532) thousand.

The average number of employees for the quarter was 26 (35) employees, of which 15 (19) are women.

Full year 2024/2025 - Sales and earnings

Net sales for the year amounted to SEK 8,619 (7,290) thousand, which is an increase of 18%, primarily attributable to a nearly threefold increase in sales in the USA. However, sales of DiviTum Kits (RUO) to the pharmaceutical industry declined compared to the previous year, as a major trial involving the kits concluded in Q3 2023/24. Sales during the year are attributable to four different product groups. These are: Tests (IVD) for the US market, DiviTum Kits (IVD) for the European market, Tests (RUO) and DiviTum Kits (RUO) which are primarily sold to the pharmaceutical industry and used for research purposes. More information is provided in Note 1
The operating loss for the year was SEK -85,839 (-126,845) thousand.

The average number of employees for the year was 27 (37) employees, of which 14 (18) are women.

Financial position, funding and investments

The closing amount for cash & cash equivalents on 30 April 2025 was SEK 24,415 (79,407) thousand. In July 2024, a directed issue was completed to secure capital for the company's ongoing launch of DiviTum TKa. The rights issue raised capital of SEK 16.4 million prior to issue costs. The subscription rate from the exercise of warrants from series TO3B was 42.7%, which generated approximately SEK 19 million to the company before issue costs. None of the warrants from series TO25B were subscribed for during April 2025.

At the extraordinary general meeting to be held on July 14, 2025, the board proposes a rights issue of a maximum of 127,122,299 shares at a price of SEK 0.63 per share, which is expected to bring the company a maximum of SEK 80 million before issue expenses. Based on the current forecast, the cash holdings of SEK 24 million at the closing date as together with the anticipated injection of SEK 80 million from the subscription guarantees associated with the rights issue announced in June 2025 (with subscription occurring in July 2025) are expected to be sufficient for meeting the company's needs until it becomes cash flow positive during the third quarter of the 2026/2027 financial year. The Board's assessment is thus that the financing for continued operations is secured and available as of the issuance of this year-end report. If current sales forecasts are not met or if delays occur, there is a risk that available cash will not be sufficient to sustain the company until it reaches positive cash flow. The Board will work with different scenarios to secure financing should that outcome occur. The various alternatives will be evaluated by the Board to arrive at the most attractive solution from the perspective of both the company and its shareholders. The Board and management have concluded that there are options for obtaining the necessary capital if that were to happen.

Net investments in property, plant and equipment in the form of equipment for the year amounted to SEK -287 (-146) thousand.

During the year, the net amount of investments in intangible assets, consisting of R&D costs and patents was SEK 0 (-0) thousand. The change is due to the fact that the current version of DiviTum TKa has reached final development. For details on impairment testing, please see the Annual Report 2023/2024. The WACC used for impairment testing during the year is 31.9% (31.3%).

Related party transactions

During the fourth quarter, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid during the quarter was SEK 68 (68) thousand. Transactions were in accordance with market-based terms and conditions.

During the 2024/2025 financial year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid during the financial year was SEK 271 (254) thousand. Transactions were in accordance with market-based terms and conditions.

During the financial year, the company engaged Jesper Söderqvist in a consulting assignment to secure capital for the Parent Company. He is a related party and member of the Board of Directors. The consulting fee for the 2024/2025 financial year amounted to SEK 328 (0) thousand. Transactions were in accordance with market-based terms and conditions.

Financial comments, Parent Company

Financial comments for the Parent Company are, in all material respects, consistent with those for the Group.

Incentive programs

Program	To	Country	Options / Share savings	Subscription price*	Option price	Subscription period	Equity Increase	Number of class B shares
TO10	Board of Directors	SE	124,454	70.35	3.94	1 August 2025 - 30 September 2025	8,297	124,454
23/26:1	Employees	US	240,000	10.13	-	1 June – 30 September 2026	16,000	240,000
23/26:2	Employees	US	56,000	10.12	-	11 July 2023 – 15 September 2026	3,733	56,000
23/26:3	Employees	SE	358,000	8.24	-	1 October- 1 November 2026	23,867	358,000
23/26:4	Board of Directors	SE	195,000	8.24	-	1 October- 1 November 2026	13,000	195,000
23/26:5	Employees	US	155,250	12.66	-	1 October- 1 November 2026	10,350	155,250
23/26:6	Employees	US	51,750	11.10	-	15 September - 1 November 2026	3,450	51,750
SSP 24/27:1	Employees	SE	621,600	2.90	-	1 October 2027- 1 November 2027	41,440	621,600
SSP 24/27:2	Board of Directors	SE	420,000	2.90	-	1 October 2027- 1 November 2027	28,000	420,000
ESOP 24/27:3	Employees	US	176,400	3.65	-	1 October 2027- 1 November 2027	11,760	176,400
PRSU 24/27:4	Employees	US	176,400	3.91	-	1 October 2027- 1 November 2027	11,760	176,400
			2,574,854				171,657	2,574,854

*In the event of variations in the subscription price stemming from performance shares, this is stated as the volume-weighted subscription price
Valuation is as per the Black & Scholes pricing model for Warrants / Options and as per Monte Carlo simulation for Share Savings Programs (23/26:3-4 & 24/27:1-2)

Incentive programs

Resolutions were passed at the EGM on 15 July 2024 on 4 programs 24/ 27: 1-4, which will be distributed during fall 2024. The programs 23/26:3-6 were never distributed due to the unfavorable stock price trend after the rights issue during fall 2023. Program TO10 has been recalculated in accordance with the program terms after the rights emission during fall 2022. The incentive programs distributed free-of-charge have been calculated and reported in accordance with IFRS 2. Accordingly, the increase in both personnel expenses (debit) and equity (credit), amounted to SEK 238 (-298) in the fourth quarter. The corresponding figure for the entire financial year is SEK 636 (32) thousand. Additional information is available in the Annual Report for 2023/2024.

Shares

As of 30 April 2025, the number of outstanding shares in Biovica was 97,786,384, of which 6,271,293 shares are Class A and 91,515,091 shares are Class B. The total number of votes amounted to 110,328,970. In July 2024, a total of 6,289,437 Class B shares were subscribed for in conjunction with the directed issue. The subscription price was SEK 2.61. In total, the company's share capital increased because of the issue by SEK 419,295.80, generating approximately SEK 16.4 million for the company before issue costs. Shareholders who participated in the rights issue were issued, free-of-charge, an additional 5 warrants of series TO25B for each share they subscribed for. More information is provided in the section, Warrants TO25B. A total of 7,441,387 warrants from the series TO3B were subscribed for in September, corresponding to the same number of shares at SEK 2.61 per share. In total, the company's share capital increased because of the issue by SEK 496,094.47, generating approximately SEK 19.4 million for the company before issue costs.

Subscription rights TO25B

In July 2024, a total of 6,289,437 Class B shares were subscribed for in conjunction with the directed issue. The subscription price was SEK 2.61. In total, the company's share capital increased because of the issue by SEK 419,295.80, generating approximately SEK 16.4 million for the company before issue costs. Shareholders who participated in the rights issue were issued, free-of-charge, an additional 5 warrants of series TO25B for each share they subscribed for. One (1) warrant from series TO25B entitles the holder to subscribe for one (1) newly issued share during the period 1 April 2025 through 30 April 2025. The subscription price was SEK 2.61. None of these subscription rights were exercised during the subscription period.

Reclassification of shares

At the end of each quarter, class A shareholders are offered the opportunity of reclassifying their shares to B shares. Reclassification from Class A to Class B shares lowers the voting power, in that Class A shares

carry three votes each and Class B shares carry one vote each. The Class A shares are unlisted, while Biovica's Class B shares are traded on Nasdaq First North Premier Growth Market, Stockholm. There was no reclassification of shares during the financial year. A table showing share capital performance will be provided on page 29 of the printed version of the annual report, which will be published during the week of 24 June 2025.

Policies for preparing the interim report

Accounting policies
This interim report was prepared in accordance with IAS 34, Interim Financial Reporting. The Group applies the Annual Accounts Act, International Financial Reporting Standards (IFRS) that have been adopted by the EU and RFR 1 Additional Accounting Regulations for Groups when preparing the financial statements. The Parent Company applies RFR 2 Accounting for Legal Entities when preparing the financial statements. The applied accounting policies correspond with those described in the Annual Report for 2023/2024.

New standards and interpretations that enter into force in 2025 and later
As of the date when these financial statements were approved for release, no new standards, revisions or interpretations of existing standards that have not yet entered into force or been published by IASB have been early-adopted by the Group.

Significant risks and uncertainties

There are a number of risks and uncertainties associated with the company's operations, including market, regulatory and financial risks. For a more detailed description of the risks (in Swedish), please see the Annual Report for 2023/2024.

Liquidity risk
Conservatism in managing liquidity risk involves holding sufficient liquid funds or agreed credit facilities in order to be able to run the business.

Based on the current forecast, the cash holdings of SEK 24 million at the closing date together with the anticipated injection of SEK 80 million from the subscription guarantees associated with the rights issue announced in June 2025 (with subscription occurring in July 2025) are expected to be sufficient for meeting the company's needs until it becomes cash flow positive during the third quarter of the 2026/2027 financial year. If current sales forecasts are not met or if delays occur, there is a risk that available cash will not be sufficient to sustain the company until it reaches positive cash flow. The Board will work with different scenarios to secure financing should that outcome occur. The various alternatives will be evaluated by the Board to arrive at the most attractive solution from the perspective of both the company and its shareholders. The Board and management have concluded that there are options for obtaining the necessary capital if that were to happen.

Uncertainties in the global situation
The Board and management continuously monitor the global situation and the increased risks arising from, among other things, Russia's invasion of Ukraine and the war in Gaza. An increased risk of trade wars and the introduction of high tariffs – particularly between Europe and the United States – could negatively impact the company's earning capacity.

Financial risk management
The Group's business activities are associated with a variety of financial risks such as currency risk and interest rate risk on cash flows, credit risk and liquidity risk. The Group's overall risk management policy, which has been established by the Board, is to strive for minimal adverse effects on financial results and financial position.

Currency risks

The Group has operations both domestically (in Sweden) and internationally, which means that there is exposure to fluctuations in different currencies, particularly USD and EUR. Currency risk arises through future business transactions and reported assets and liabilities. The increased scope of the company's operations has increased its net exposure to foreign currencies compared to prior years.

Interest rate risk on cash flows
Interest rate risk is the risk that the value of financial instruments will fluctuate due to changes in market interest rates. The Group currently only has interest-bearing financial assets in the form of bank balances, which is why this risk is assessed as low.

Credit risk
Credit risk is the risk that a party to a transaction involving a financial instrument is unable to fulfill its obligation. Exposure to credit risks is marginal for both the Group and Parent Company.

Significant assessments

Assessments and estimates in the financial statements
In preparing the financial statements, the executive management team must make assessments and estimates that affect both the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The actual outcome may deviate from these estimates and assessments. A selection of these assessments is presented below.

Revenue from contracts with customers
Revenue from contracts with customers is reported at net realizable value and recognized when the performance obligation has been fulfilled and control over the goods or services has been transferred to the customer, in accordance with IFRS 15. This assessment shall occur from the customer's perspective, taking into consideration such things as transfer of ownership and risks, the customer's acceptance, physical access and the right to invoice. An assessment must also be made of whether control has been transferred at a specific point in time, or over time. All net sales are sales at a particular point in time. No sales are reported as sales over time. The timing of revenue recognition for services coincides with the reporting of test results to the customer. For goods, revenue is recognized when the risks and rewards associated with the item are transferred to the customer. Revenue is recognized at net realizable value at a specific point in time, which is when control of the goods or services has been transferred to the customer. The contract terms and conditions may vary but typically, transfer of control and thus revenue recognition occurs at the time of delivery.

Segment reporting
The Group's operations consist of development, manufacturing and sales of blood analysis products. The Group's organizational structure is by function as follows: production, sales & marketing, administration and R&D. The Group is considered to be a single unit, where all of its sub-components are integrated and dependent upon each other. Biovica's highest decision-making body monitors the consolidated income statement and statement of comprehensive income.

Intangible assets
Expenditure for research that is for the purpose of gaining new scientific or technical knowledge is expensed as incurred. Expenditure for development (where the research results or other knowledge is used to achieve new or improved products or processes) is recognized as an intangible fixed asset in the statement of financial position if the product or process is technically or commercially usable and the company has adequate resources for monitoring the development and thereafter using or selling the intangible asset. Decisions on whether or not to capitalize expenditure on development projects are made by the company's Board of Directors based on documentation and support provided by the Audit Committee. The decision is based on whether it is possible to implement the project using existing or future resources and on whether conclusion of the project and launch is expected to occur in the foreseeable future. Directly attributable expenditure that is capitalized as part of the cost of the asset includes expenditure for employees and materials. With capitalization, consideration is given to the portion of expenditure recognized as revenue against received/expected grants. Capitalized development expenditure is reported as intangible assets and amortized as of the date when the asset is ready for use. The estimated useful life for capitalized development expenditures is 10 years. Other development expenses are recognized in the income statement as incurred. Patents are recognized at the cost of acquisition and they are amortized on a straight-line basis over their estimated useful lives. The estimated useful life is assessed based on the legal life of the patent.

For a detailed description of these assessments, please see the Annual Report for 2023/2024.

Note 1. Sales per product group

Net sales are derived from the following product groups:

	Q4 24/25	Q4 23/24
Tests (IVD) - US	934	424
DiviTum Kits (IVD) - EU	0	0
Research Test	329	677
DiviTum Kits ROU	1,069	798
Net sales, total	**2,332**	**1,899**

	May-April 24/25	May-April 23/24
Tests (IVD) - US	2,953	788
DiviTum Kits (IVD) - EU	264	0
Research Test	2,280	2,000
DiviTum Kits ROU	3,123	4,502
Net sales, total	**8,619**	**7,290**

KPIs for the Group

SEK 000s	Q4 24/25	Q4 23/24	Full year 24/25	Full year 23/24
Net sales	2,332	1,899	8,619	7,290
Operating profit (loss)	-20,341	-41,490	-85,839	-126,845
Profit (loss) for the period	-20,766	-39,532	-87,624	-124,823
Capitalized R&D costs	0	0	0	0
Capitalized R&D exp., % of op. expenses	0	0	0	0
Earnings per share, before dilution	-0.21	-0.47	-0.95	-2.14
Earnings per share, after dilution	-0.21	-0.47	-0.95	-2.14
Cash and cash equivalents at the end of the period	24,415	79,407	24,415	79,407
Cash flow from operating activities	-17,826	-25,251	-85,367	-114,574
Cash flow for the period	-18,748	-26,173	-54,730	-35,658
Equity	43,206	96,639	43,206	96,639
Equity per share	0.44	1.15	0.44	1.15
Equity ratio (%)	67%	74%	67%	74%
Average number of employees	26	35	27	37

Definitions are the same as those presented in the Annual Report for 2023/2024.

Alternative key performance indicators

Of the KPIs presented above, the only one that is obligatory to report, and which is defined in accordance with IFRS is: Earnings per share, before and after dilution. For the other KPIs, the following are in accordance with IFRS presentation requirements: Profit (loss) for the year, Cash & cash equivalents at the end of the period, Cash flow for the period and Equity.

KPIs	Definition	Reason for using alternative KPIs, which are not defined in accordance with IFRS.
Net sales	Income from goods sold	Shows the demand for the product.
Operating profit (loss)	Profit (loss) before financial items and tax.	Operating profit (loss) is an indication of the company's earnings generated from ordinary operations.
Earnings per share, before and after dilution	Profit (loss) divided by the weighted average number of shares during the period, before and after dilution.	
Cash & cash equivalents and short-term investments	Bank balances and short-term investments	
Cash flow from operating activities	Cash flow before the cash flow from investing activities and financing activities	
Cash flow for the period	Change in cash & cash equivalents for the period not including the effect from unrealized exchange gains and losses.	
Equity per share	Equity divided by the number of shares at the end of the period.	Management uses this KPI to monitor the value of equity per share.
Equity ratio	Equity as a percentage of total assets.	Management uses this KPI because it provides an indication of the company's financial stability.
Average number of employees	The average number of employees is calculated as the average during the period of the number of employees per month.	

Consolidated income statement and summary statement of comprehensive income

	Q4 24/25	Q4 23/24	May-April 24/25	May-April 23/24
Amount in SEK thousands				
Net sales	2,332	1,899	8,619	7,290
Other income	932	343	2,341	1,013
Work performed by the company and capitalized	0	0	0	0
Operating income	**3,264**	**2,243**	**10,961**	**8,304**
Materials cost	125	-647	-535	-413
Other external costs	-7,141	-10,080	-28,332	-37,523
Employee benefit expenses	-13,630	-30,282	-57,299	-85,998
Depreciation/amortization	-2,160	-2,368	-8,843	-9,429
Other operating expenses	-798	-356	-1,791	-1,785
Operating expenses	**-23,604**	**-43,733**	**-96,800**	**-135,149**
Operating profit (loss)	**-20,341**	**-41,490**	**-85,839**	**-126,845**
Financial income	346	723	774	2,998
Financial expenses	-246	-67	-917	-289
Profit (loss) before tax	**-20,240**	**-40,834**	**-85,983**	**-124,136**
Tax	-526	1,302	-1,641	-687
Profit (loss) for the period	**-20,766**	**-39,532**	**-87,624**	**-124,823**
Consolidated statement of comprehensive income				
Profit (loss) for the period	-20,766	-39,532	-87,624	-124,823
Exchange differences when translating foreign operations	0	224	0	294
Other comprehensive income for the period	0	0	0	0
Comprehensive income for the period	**-20,766**	**-39,308**	**-87,624**	**-124,530**
Earnings per share				
Earnings per share, before dilution (SEK)	-0.21	-0.47	-0.95	-2.14
Average number of shares, before dilution	97,786,384	84,055,560	92,569,248	58,408,099
Earnings per share, after dilution (SEK)	-0.21	-0.47	-0.95	-2.14
Average number of shares, after dilution	97,786,384	84,055,560	92,569,248	58,408,099

Consolidated statement of financial position, in summary

Amount in SEK thousands	2025-04-30	2024-04-30
ASSETS		
Intangible assets	26,536	31,602
Machinery, equipment, tools, fixtures and fittings	1,049	1,179
Right-of-use assets	3,719	6,935
Other non-current receivables	396	449
Deferred tax asset	2,455	3,127
Total fixed assets	**34,154**	**43,292**
Inventories	1,930	2,199
Accounts receivable	1,815	1,667
Current receivables	2,634	4,843
Cash and bank	24,415	79,407
Total current assets	**30,794**	**88,115**
TOTAL ASSETS	**64,949**	**131,408**
EQUITY		
Share capital	6,519	5,604
Other contributed capital	577,824	543,918
Reserves	-222	410
Retained earnings (losses), including loss for the year	-540,915	-453,291
Total equity	**43,206**	**96,640**
LIABILITIES		
Right-of-use liabilities	1,736	4,296
Deferred tax liability	1,849	2,180
Total non-current liabilities	**3,585**	**6,476**
Right-of-use liabilities	2,915	3,532
Advance payments from customers	0	19
Accounts payable	3,544	3,028
Current tax liabilities	14	229
Other liabilities	912	1,181
Accrued expenses and deferred income	10,774	20,303
Current liabilities	**18,158**	**28,291**
TOTAL EQUITY AND LIABILITIES	**64,949**	**131,408**

Consolidated statement of changes in equity, in summary

Amount in SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings	Total equity
Opening balance, 1 May 2023	**3,049**	**463,938**	**116**	**-328,468**	**138,636**
Appropriation in accordance AGM decision					0
New share issue	2,554	96,566			99,121
Issue fees		-16,650			-16,650
Share-based payments, employees		64			64
Transaction with owners	**5,604**	**543,918**	**116**	**-328,468**	**221,170**
Profit (loss) for the year				-124,823	-124,823
Other comprehensive income			294		294
Comprehensive income for the year (loss)	**0**	**0**	**294**	**-124,823**	**-124,530**
Closing balance, 30 April 2024	**5,604**	**543,918**	**410**	**-453,291**	**96,640**
Opening balance, 1 May 2024	**5,604**	**543,918**	**410**	**-453,291**	**96,640**
Appropriation in accordance AGM decision					0
New share issue	915	34,922			35,837
Issue fees		-1,604			-1,604
New issue of shares via exercise of warrants		588			588
Transaction with owners	**6,519**	**577,824**	**410**	**-453,291**	**131,462**
Profit (loss) for the year				-87,624	-87,624
Other comprehensive income			-632		-632
Comprehensive income for the year (loss)	**0**	**0**	**-632**	**-87,624**	**-88,256**
Closing balance, 30 April 2025	**6,519**	**577,824**	**-222**	**-540,915**	**43,206**

Consolidated statement of cash flows, in summary

Amount in SEK thousands	Q4 24/25	Q4 23/24	May-April 24/25	May-April 23/24
Cash flow from operating activities before changes in working capital	**-18,045**	**-38,417**	**-77,113**	**-117,298**
Change in current receivables	-1,183	304	-216	-398
Change in current liabilities	2,051	12,175	-7,953	3,708
Change in inventories	-649	686	-85	-588
Changes in working capital	**219**	**13,165**	**-8,254**	**2,722**
Cash flow from operating activities	**-17,826**	**-25,251**	**-85,367**	**-114,575**
Investing activities				
Investments in PPE	-78	-146	-287	-146
Investments in financial assets	0	1	0	-439
Cash flow from investing activities	**-78**	**-144**	**-287**	**-585**
Financing activities				
New share issue	0	-145	35,837	99,121
Issue fees	0	0	-1,604	-16,650
Amortization of loans	-844	-634	-3,309	-2,968
Cash flow from financing activities	**-844**	**-779**	**30,925**	**79,502**
Cash flow for the period	**-18,748**	**-26,175**	**-54,730**	**-35,658**
Cash and cash equivalents at the beginning of the period	43,508	105,238	79,407	114,327
Translation difference, cash and cash equivalents	-345	344	-262	737
Cash and cash equivalents at the end of the period	24,415	79,407	24,415	79,407

Parent Company income statement, in summary

Amount in SEK thousands	Q4 24/25	Q4 23/24	May-April 24/25	May-April 23/24
Net sales	5,272	11,502	28,385	27,965
Other operating income	932	343	2,341	1,013
Total revenue	**6,204**	**11,845**	**30,726**	**28,979**
Materials cost	198	-160	-640	74
Other external costs	-18,970	-41,743	-78,062	-114,721
Employee benefit expenses	-7,521	-11,652	-33,024	-35,281
Depreciation/amortization	-1,242	-1,493	-5,217	-5,966
Other expenses	-798	-356	-1,791	-1,785
Operating expenses	**-28,334**	**-55,403**	**-118,734**	**-157,680**
Operating profit (loss)	**-22,130**	**-43,558**	**-88,008**	**-128,701**
Financial income	0	1,049	18	2,338
Financial expenses	-550	0	0	0
Profit (loss) before tax	**-22,680**	**-42,509**	**-87,990**	**-126,363**
Tax on profit for the year	0	0	0	0
Profit (loss) for the period	**-22,680**	**-42,509**	**-87,990**	**-126,363**

Comprehensive income (loss) equals the loss for the period.

Parent Company balance sheet, in summary

Amount in SEK thousands	2025-04-30	2024-04-30
ASSETS		
Intangible assets	26,536	31,602
Machinery, equipment, tools, fixtures and fittings	636	499
Financial assets	4,082	7,606
Total fixed assets	**31,254**	**39,707**
Inventories	1,866	2,122
Current receivables	2,915	3,932
Cash and bank	22,722	77,105
Total current assets	**27,504**	**83,159**
TOTAL ASSETS	**58,758**	**122,867**
EQUITY		
Restricted equity	27,567	29,989
Non-restricted equity	13,491	64,238
Total EQUITY	**41,059**	**94,227**
LIABILITIES		
Current liabilities	17,699	28,640
Total LIABILITIES	**17,699**	**28,640**
TOTAL EQUITY AND LIABILITIES	**58,758**	**122,867**

Glossary

Abstract A short summary of a longer document, such as a dissertation or research article. It briefly states the purposes and results of the research. Abstracts are submitted to scientific conferences in order to spread knowledge of new research.

Imaging These are methods that currently serve as the cornerstones for diagnostics and treatment planning for essentially all types of solid tumors. It includes computer tomography (CT) scans and other X-ray methods, magnetic resonance tomography (MRT) scans, positron emission tomography (PET) scans and ultrasound.

CDK4/6 inhibitors A new type of targeted, selective drugs that have been shown to be effective against several forms of cancers, including hormone receptor-positive breast cancer.

CLIA laboratory (The Clinical Laboratory Improvement Amendments): a clinical laboratory that has been certified to accept human samples from people in the USA for diagnostic testing. The Center for Medicare and Medicaid Services (CMS) is the regulatory body that grants certification.

Companion Diagnostics Also called CDx. These are diagnostic tests used to identify patients that would likely respond to a specific treatment, as well as to monitor the treatment effect on individual patients. They thus facilitate personalization of treatment.

Fulvestrant (Faslodex) A drug that is used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression and HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine treatment. Fulvestrant is a Selective Estrogen Receptor Degrader (SERD).

IVD In vitro diagnostics (IVD) are generally defined as a product which, regardless of whether they are used alone or in combination, are designed for performing in vitro tests on samples that have been taken from the human body. The main purpose is to obtain information for diagnostic, monitoring or compatibility purposes.

KOL Key Opinion Leaders. Trusted, well-respected influencers with proven experience in a particular field.

Palbociclib A new type of targeted, selective drug that has been shown to be effective against several forms of cancers, including hormone receptor-positive breast cancer.

Poster session An event held at a congress or conference with an academic or professional focus to present research information in the form of a paper poster that conference participants may view. A poster session is an event at which many such posters are presented.

Posters These are used to summarize information or research and present it in an attractive way as a means of generating interest in publishing it and sparking discussion at events such as scientific conferences.

Predictive Anticipation about what will happen in the future and used in the contexts like the predictive ability of a particular test.

PREDIX study A randomized trial of neoadjuvant chemotherapy to treat HER2-positive breast cancer that was carried out during the period 2014–2019 at nine Swedish clinics under the supervision of Karolinska Institutet (KI).

Prospective studies Used to study the relationship between various risk factors and a particular disease. This type of study follows individuals both with risk factors and without (the control group), for a period of time into the future. At the end of the study, a comparison is made of the percentage that fell ill in each group.

PYTHIA study A clinical study of patients with metastatic breast cancer. The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the selection of patients to Palbociclib/Fulvestrant treatment.

Reimbursement Compensation for costs (in this context, it is payment from insurance companies to cover treatment costs)

SABCS San Antonio Breast Cancer Symposium is an international scientific symposium on breast cancer held each year in December in San Antonio Texas, USA.

RUO Research Use Only An ROU product is an IVD (In Vitro Diagnostic) product that is in the development stage and may only be used for laboratory research and clinical studies.

Tymidine kinase is an enzyme (kinase), subclass of phosphotransferase.

Estrogen receptor-positive To determine whether a patient might benefit from hormone treatment, the tumor is studied to assess whether receptors for either estrogen or progesterone. If so, it is hormone-receptor positive, which is the case for around 70 percent of all breast cancer tumors. It is primarily estrogen that has a stimulating effect on tumor growth.

This report has not been reviewed by the company's auditor.

Board of Directors' assurance

The Board of Directors and CEO hereby certify that this interim report provides a true and fair summary of the Parent Company's and the Group's operations, earnings and financial position as well as describing any significant risks or uncertainties faced by the Parent Company or any of the companies belonging to the Group.

Uppsala, 18 June 2025

Lars Holmqvist
Chairman of the Board

Annika Carlsson Berg
Board member

Marie-Louise Fjällskog
Board member

Maria Holmlund
Board member

Jesper Söderqvist
Board member

Anders Rylander
CEO, Board Member

Calendar

Annual Report 2024/2025	week of 23 June 2025
Interim Report for Q1: May-July 2025/2026	11 September 2025
AGM 2025	16 September 2025
Interim Report for Q2: August-October 2025/2026	18 December 2025
Interim Report for Q3: November-January 2025/2026	18 March 2026
Interim Report for Q4: February-April 2025/2026	17 June 2026

For more information, please contact:

Anders Rylander, CEO
Phone: +46 (0)18-44 44 835
E-mail: anders.rylander@biovica.com

Anders Morén, CFO
Phone +46 (0)73 125 92 46
E-mail: anders.moren@biovica.com

Biovica International AB (publ), 556774-6150
Dag Hammarskjölds väg 54B
752 37 Uppsala
+46 (0)18-44 44 830

Biovica – Treatment decisions with greater certainty

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum Tka, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The first application for DiviTum TKa is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum TKa has obtained FDA 510(k) clearance in the USA and has CE marking in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com